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Abstract
The molecular determinants underpinning how hexaacylated lipid A and tetraacylated precursor lipid IVa activate Toll-like
receptor 4 (TLR4) are well understood, but how activation is induced by other lipid A species is less clear. Species specificity
studies have clarified how TLR4/MD-2 recognises different lipid A structures, for example tetraacylated lipid IVa requires
direct electrostatic interactions for agonism. In this study, we examine how pentaacylated lipopolysaccharide from
Rhodobacter sphaeroides (RSLPS) antagonises human TLR4/MD-2 and activates the horse receptor complex using a
computational approach and cross-species mutagenesis. At a functional level, we show that RSLPS is a partial agonist at
horse TLR4/MD-2 with greater efficacy than lipid IVa. These data suggest the importance of the additional acyl chain in
RSLPS signalling. Based on docking analysis, we propose a model for positioning of the RSLPS lipid A moiety (RSLA) within
the MD-2 cavity at the TLR4 dimer interface, which allows activity at the horse receptor complex. As for lipid IVa, RSLPS
agonism requires species-specific contacts with MD-2 and TLR4, but the R2 chain of RSLA protrudes from the MD-2 pocket
to contact the TLR4 dimer in the vicinity of proline 442. Our model explains why RSLPS is only partially dependent on horse
TLR4 residue R385, unlike lipid IVa. Mutagenesis of proline 442 into a serine residue, as found in human TLR4, uncovers the
importance of this site in RSLPS signalling; horse TLR4 R385G/P442S double mutation completely abolishes RSLPS activity
without its counterpart, human TLR4 G384R/S441P, being able to restore it. Our data highlight the importance of subtle
changes in ligand positioning, and suggest that TLR4 and MD-2 residues that may not participate directly in ligand binding
can determine the signalling outcome of a given ligand. This indicates a cooperative binding mechanism within the
receptor complex, which is becoming increasingly important in TLR signalling.
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Introduction
The Toll-like receptor (TLR) family is the most widely studied
pattern recognition receptor family, comprising 13 mammalian
members, of which 10 are expressed in humans [1]. Toll-like
receptor 4 (TLR4) is expressed on the plasma membrane and
endosomes to sense lipopolysaccharide (LPS) from Gram-negative
bacteria, requiring the co-receptor MD-2 to bind the lipid
component of LPS (lipid A) and form the active complex [2,3].
The crystal structure of human and mouse TLR4/MD-2 bound to
E. coli LPS (ECLPS) demonstrates a heterotetrameric structure,
comprising two TLR4, two MD-2 and two LPS molecules [4,5].
Five of the six lipid A acyl chains sit deep within the MD-2 pocket,
and the sixth (R2 chain) protrudes from the MD-2 pocket to form
part of the dimerisation interface with the opposing TLR4
(denoted thereafter TLR4*).
TLR4/MD-2 from all domestic mammalian species recognises
hexaacylated lipid A from E. coli (figure 1A) as an agonist, but
structural variability in lipid A from other Gram-negative
organisms alters their efficacy (maximum stimulation, Emax) and
potency (half maximum effective concentration, EC50) at the
receptor complex. A reduction in acyl chain number from six to
four in the lipid A synthesis intermediate lipid IVa (figure 1B)
makes this compound an antagonist at TLR4/MD-2, but only in
humans. At horse and mouse TLR4/MD-2, lipid IVa is an
agonist, with residues R385 in horse TLR4, and K367 and R434
in mouse TLR4, being important for agonist activity [6,7,8,9].
Eritoran, a tetraacyl chain lipid A analogue derived from the
structure of Rhodobacter sphaeroides LPS (RSLPS), is an antagonist at
human, mouse and horse TLR4/MD-2.
Antagonist-conformation crystal structures of human TLR4/
MD-2 proteins bound to lipid IVa and eritoran demonstrate gross
similarities to each other and significant differences to lipid A
[10,11]. Their relative orientations in the MD-2 lipid-binding
pocket are inverted, with either the 49-phosphate (49-PO4) in the
antagonist conformation or the 1-PO4 in the agonist conformation
facing the LPS-binding motif of MD-2 [4,5,10,11,12]. Both
ligands have only four acyl chains, which are fully accommodated
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within the MD-2 binding pocket. A recent crystal structure of lipid
IVa bound to mouse TLR4/MD-2 demonstrates that lipid IVa
can nevertheless form similar interactions to E. coli lipid A in the
presence of appropriate surface charge distribution on TLR4/
MD-2 [5]. This results in a 4–7 A˚ difference in glucosamine
backbone position along a 180u rotation between human- and
mouse-bound lipid IVa conformations. The positioning of the
ligand triggers conformational switching in MD-2 and dimerisa-
tion of TLR4 for agonists, and apparently fails to do so in the case
of antagonists. It is not clear, however, whether novel lipid A
structures will also share similar interacting properties. Subtle
differences exist in the interaction patterns of lipid IVa and lipid A
at the TLR4/MD-2 complex, and these probably underlie the
small differences in efficacy between the two ligands at mouse
TLR4/MD-2 [5]. The mouse lipid IVa-TLR4-MD-2 complex is
monomeric in solution, but dimeric within crystals as a result of
crystal packing. At the molecular level, the mouse TLR4 dimer
interface residues K367* and R434* both contact the lipid IVa
and lipid A 1-PO4 groups, whereas an extra hydrogen bond forms
between lipid A/TLR4. This extra bond is, therefore, most likely
required for maximal ligand efficacy.
Lipid A from Rhodobacter sphaeroides (RSLA; figure 1C) has five
acyl chains, with an extended and unsaturated R20 acyl chain, two
shortened chains (R3 and R39), and absent R30 chain in
comparison to E. coli lipid A [13]. RSLPS is an antagonist at
human and mouse TLR4/MD-2, but an agonist at horse TLR4/
MD-2. The agonist activity of RSLPS, like lipid IVa, requires both
species-specific TLR4 and MD-2 [14]. In this study, we identify
the regions of TLR4 and MD-2 required for RSLPS agonist
activity. Two specific amino acid residues in horse TLR4 are
required for full RSLPS signalling (R385 and P442). RSLPS has
increased efficacy compared to lipid IVa, which is most likely due
to differences in positioning between RSLA and lipid IVa affecting
how the 1-PO4, 49-PO4 and R2 chain interact with TLR4 and
TLR4*. Interestingly, residues critical in conferring RSLPS




The plasmid vector pEFIRES was generated by removal of the
BamHI restriction site from pEFIRES-P as described previously
[15]. Plasmids containing cDNA were as follows: human and
horse TLR4 (hTLR4 and eqTLR4 respectively) in pcDNA3;
human and horse CD14 (hCD14 and eqCD14 respectively) in
pcDNA3; human and horse MD-2 (hMD-2 and eqMD-2
respectively) in pEFIRES. Chimeric receptors with domain
exchange between species were generated by overlap extension
PCR using Phusion High-Fidelity DNA Polymerase (Finnzymes).
Mutant receptors with single point mutations were generated by
site-directed mutagenesis using Pfu polymerase (Fermentas).
Cell culture and transient transfection
Human Embryonic Kidney 293 (HEK293) cells were purchased
from ATCC and maintained in Dulbecco’s Modified Eagle’s
medium (Sigma) containing 10% foetal calf serum (FCS; Hyclone),
2 mM l-glutamine, 100 iu/ml penicillin and 100 mg/ml strepto-
mycin (referred to as complete culture medium). Cells were plated
onto a 96 well plate at 36104 cells/well and transfected two days
later. Differing combinations of plasmid-cDNA together with the
reporter vectors pNF-kB-luc (Clontech), encoding a firefly
luciferase under an NF-kB promoter, and phRG-TK (Promega),
encoding a constitutively expressed Renilla luciferase, were
transfected into the cells using jetPEI (Polyplus) according to the
manufacturer’s instructions. Briefly, plasmids were mixed in the
desired amounts before being added to jetPEI in 150 mM NaCl.
Mixtures were incubated for 30 minutes before being diluted in
complete culture medium. Old medium was removed from plated
cells and replaced with the plasmid mixtures. Plasmid-cDNA
Figure 1. Chemical structures of lipid A derivatives. A) Lipid A from E. coli. B) Lipid A synthesis intermediate lipid IVa. C) Lipid A from
Rhodobacter sphaeroides.
doi:10.1371/journal.pone.0098776.g001
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amounts per well were as follows: TLR4-pcDNA3 1 ng, MD-2-
pEFIRES 1 ng, CD14-pcDNA3 1 ng. Reporters were added at
10 ng/well pNF-kB-luc and 5 ng/well phRG-TK. To maintain a
constant amount of DNA (100 ng) per well, DNA amounts were
adjusted with empty pcDNA3. Cells were stimulated two days
after transfection.
Lipopolysaccharides
Phenol-extracted LPS from E. coli O157:B8 (ECLPS) was
purchased from Sigma. Ultrapure LPS from Rhodobacter sphaeroides
(RSLPS) was purchased from Invivogen. Lipid IVa was purchased
from Pepta Nova. RSLPS and ECLPS were reconstituted in sterile
endotoxin-free water (Sigma) to 1 mg/ml. Lipid IVa was
reconstituted in sterile DMSO to 1 mg/ml. All LPS derivatives
were sonicated prior to freezing at 220uC in aliquots and then re-
sonicated for one minute following thawing before use.
Stimulation of cells
ECLPS, RSLPS and lipid IVa were diluted in Dulbecco’s
Modified Eagle’s medium containing 0.1% FCS, 2 mM l-
glutamine, 100 iu/ml penicillin and 100 mg/ml streptomycin
(referred to as 0.1% FCSM). 0.1% FCS was added to stimulation
media to provide a source of LPS binding protein without addition
of excessive bovine MD-2 [15]. ECLPS was used at 10 ng/ml,
RSLPS was used at 100 ng/ml and lipid IVa was used at 1 mg/ml
final concentration; these concentrations were determined by
dose-response analysis (figure 2A and 2C; not shown for lipid IVa)
to give a maximal agonist response by RSLPS and lipid IVa at
horse TLR4 and a strong inhibition of ECLPS at human TLR4.
Medium containing transfection reagent was removed from cells
and replaced with one of 0.1%FCSM alone, RSLPS, ECLPS,
ECLPS+RSLPS, lipid IVa or lipid IVa+ECLPS, and cells
incubated for 6 hours at 37uC/5% CO2. Media were then
removed and cells washed with 200 ml warmed PBS. Diluted
Passive Lysis Buffer (PLB; Promega) was added at 50 ml per well
and luciferase activity determined using the Dual-Luciferase Assay
kit (Promega) according to the manufacturer’s instructions.
Receptor alignments and sequence variation analysis
Receptor sequences for human, horse, mouse, cat and rat TLR4
were entered into the ClustalW multiple sequence alignment tool
to generate a Protein Information Resource format alignment.
Sequences were then entered into the online TraceSuite ii server
(http://mordred.bioc.cam.ac.uk/,jiye/evoltrace/evoltrace.html)
to assess sequence variation and define residues present in the
horse only.
Structural templates for human TLR4-MD-2
The crystal structure of human MD-2 in complex with lipid IVa
was chosen to represent a typical inactive conformation of
antagonist-bound MD-2 [11]. The crystal structure of human
TLR4/MD-2 was used to represent the active conformation of
TLR4/MD-2 [4,5]. The coordinates of lipid IVa and LPS were
removed from the Protein Data Bank files 2E59 and 3FXI
respectively. The monomeric MD-2 structure extracted from 2E59
and the dimeric TLR4/MD-2 structure from 3FXI were then
used in the docking experiments.
Homology modelling of horse TLR4-MD-2
Horse TLR4 and MD-2 proteins were modelled using the
human and mouse complexes [4,5]. Homology models were built
using Modeller software [16]. The best model was chosen based
on the lowest energies and violations as calculated by Modeller. A
further quality assessment of the model was performed using
Verify3D and also Ramachandran plot analysis, which was carried
out with Molprobity [17,18].
In silico construction of RSLA
The crystal structures for eritoran, as observed in complex with
human MD-2, an N-terminal truncation of TLR4 with ECLPS in
complex with human MD-2, and the non-truncated ectodomain of
Figure 2. RSLPS is a partial agonist at horse TLR4/MD-2 and
competitive antagonist at human TLR4/MD-2. HEK293 cells were
transiently transfected with horse or human TLR4, MD-2 and CD14,
together with reporter constructs NF-kB-luc and phRG-TK. Cells were
stimulated 48 hours later for 6 hours. Data are from a representative
experiment (n = 3 experiments) and expressed as triplicate mean 6SEM
for that experiment, relative to the maximum ECLPS response. A and B)
Horse TLR4/MD-2/CD14-transfected cells were stimulated with increas-
ing concentrations of RSLPS or increasing concentrations of ECLPS (A),
or increasing concentrations of RSLPS+10 ng/ml ECLPS (B). C) Human
TLR4/MD-2/CD14-transfected cells were stimulated with increasing
concentrations of ECLPS in the presence of 0, 1, 10 and 100 ng/ml
RSLPS.
doi:10.1371/journal.pone.0098776.g002
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human TLR4 were used as templates to build RSLA molecules
[4,10]. Eritoran and the ECLPS structure were extracted from the
corresponding PDB files and processed in Sybyl version 8.1.1
(Tripos), in order to generate RSLA. Sybyl software allowed
editing of existing moieties and modelling of additional chemical
groups in the first instance. Geometry optimisation was then
carried out using the Powell minimisation method, with initial
optimisation based on the Simplex method, and with a gradient of
0.05 kcal/mol and a maximum of 100 cycles of iteration. Partial
charges were computed based on the Gasteiger-Hu¨ckel charge
method.
Molecular docking
Molecular docking of RSLA molecules was carried out using the
Autodock 4.0 software package [19]. The receptor models of
inactive MD-2 and active TLR4/MD-2 were treated as rigid
molecules. Although engagement of two agonist ligands are
required to generate the active TLR4/MD-2 heterotetrameric
complex, only one docking event was calculated, in keeping with
the binding symmetry. The lipid A acyl chains were kept semi-
flexible with the maximum allowed torsion angles during docking,
ie. 32 torsions. The Autogrid parameters were computed on a grid
size 42666670 A˚3, with a spacing of 0.375 A˚. The grid was
centred on lipid A in the hydrophobic cavity of active MD-2 at
x = +29.008; y =28.418; z = +17.182. Unless stated otherwise,
parameters were kept at their default values. Hundred docking
poses of the ligand were generated using the Lamarckian version
of genetic algorithm searches. The protocol is based on the
optimisation of an initial population of 150 randomly-placed
individuals, a maximum number of 2.5 million energy evaluations,
a maximum number of 27,000 generations with a mutation rate of
0.02, and a cross-over rate of 0.8. The lowest energy complexes
were analysed in depth. Structural images were generated in
PyMol, and atomic distances measured using the PyMol
measurement wizard.
Statistical methods
Experiments were repeated three times to ensure qualitative
repeatability, and data are expressed as a representative
(single) experiment. Data except figure 2C are shown as a
percentage of the maximum horse TLR4/MD-2 ECLPS
response for comparison between different experiments
[9,20,21]. Figure 2C is expressed as a percentage of the
maximum human ECLPS response. Statistical analyses were
performed on individual experiments. Error bars are defined as
the standard error of the mean (SEM) for the representative
experiment, and calculated using triplicate replicates for that
value within that experiment. Dose response curves were fitted
by non-linear regression to a sigmoidal dose-response (variable
slope) model, using GraphPad Prism software, to allow
determination of EC50 and the associated 95% confidence
intervals (CI). For comparison of curves, best-fit values for
maximum stimulation and logEC50 were compared using F
tests. Bar graph values were compared using an unpaired two-
tailed students’t-test with Welch’s correction for unequal
variance (as required), and with Bonferroni correction for
multiple comparisons.
Results
Residues 55-107 of MD-2 and LRR14-17 of TLR4 are
important for the agonist activity to RSLPS
Dose-response assays confirmed RSLPS activates horse TLR4/
MD-2, but also dose-dependently inhibits ECLPS activity
(figures 2A and 2B). Maximum stimulation by RSLPS at horse
TLR4, as determined by nonlinear regression, was significantly
lower than by ECLPS (88% ECLPS activity) (figure 2A). These
data show that RSLPS is a partial agonist with high efficacy at
horse TLR4. The EC50 for RSLPS at horse TLR4 was 37 ng/ml
(95% CI 33–42 ng/ml), which is significantly greater than for
ECLPS at 1.8 ng/ml (95% CI 1.4–2.3 ng/ml) (figure 2A). Our
work previously defined the EC50 for lipid IVa at horse TLR4 as
5 ng/ml, and lipid IVa efficacy as significantly lower than ECLPS
at 55.5% activation [15]. RSLPS would seem to have a lower
potency and higher efficacy than lipid IVa. The exact molecular
weight is not known for RSLPS, in particular since non-synthetic
LPS is heterogeneous, however we estimate it to be a 10-fold order
of magnitude (10–20 kDa) compared to lipid IVa (1.4 kDa). The
potency of RSLPS is, therefore, within the same range as that of
lipid IVa (approximately 1.8–3.7 nM compared to 3.6 nM,
respectively). RSLPS dose-dependently inhibited ECLPS activa-
tion of human TLR4/MD-2 without inducing any agonist
response, confirming it is a competitive TLR4 antagonist in this
species (figure 2C) [22].
RSLPS stimulation, as shown previously, required both
horse TLR4 and horse MD-2 to induce agonist activity
(figure 3A) [14]. CD14 sensitised ECLPS activation of
TLR4/MD-2, but had no effect on the agonist activity of
RSLPS (figure 3B).
Residues 57–107 of horse MD-2 are essential for signalling to
lipid IVa [9]. Aligned human and horse MD-2 sequences are
shown in figure S1. A chimera in which horse MD-2 residues
55–107 are replaced with the equivalent human MD-2 residues,
when transfected with horse TLR4, failed to signal to RSLPS
(figure 3C). The complementary chimera containing residues
55–107 of horse MD-2 within the human MD-2 framework
signalled to RSLPS, suggesting these residues are as important
for signalling to RSLPS as they are for lipid IVa signalling.
Neither MD-2 chimera signalled to RSLPS with human TLR4
(not shown). Within 57–107, residues 57–79 of horse MD-2 are
essential for lipid IVa signalling, and are sufficient to confer
lipid IVa agonist activity onto human MD-2 [15]. A loss of
agonist activity was seen with RSLPS, as for lipid IVa, when
residues 55–79 of horse MD-2 were replaced with the equivalent
human residues (figure 3C). This region of MD-2 was not,
however, able to confer RSLPS signalling onto human MD-2.
Unlike for lipid IVa, residues within 80–107 are therefore also
required for full RSLPS agonist activity. These data suggest that
RSLPS may form a wider interface with horse MD-2 than lipid
IVa.
LRR14-17 (residues 373–476) of horse TLR4 are critical for
lipid IVa agonist activity, and this region of horse TLR4 is
sufficient to confer signalling to lipid IVa onto human TLR4
[9]. Sequence alignments for this region are shown in figure
S2. Using a chimera of horse TLR4 containing the human
LRR14-17 (residues 372–475), co-expressed with horse MD-2,
switched RSLPS to an antagonist as observed for lipid IVa
(figure 3D). The complementary chimera, however, did not
signal to RSLPS when transfected with horse MD-2. Neither
construct signalled to RSLPS with human MD-2 (data not
shown). These data suggest LRR14-17 are important for
RSLPS agonist activity, but residues outside LRR14-17 also
contribute to RSLPS signalling. This was confirmed by
replacing LRR9 onwards of human TLR4 with the corre-
sponding horse residues, which resulted in conferring respon-
siveness to RSLPS when transfected with horse MD-2
(figure 3D). The agonist activity of RSLPS at horse TLR4
was lost when LRR9 onwards was replaced with the
Rhodobacter sphaeroides LPS Pharmacology at Horse TLR4/MD-2
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corresponding human residues and transfected with horse MD-
2. Replacing horse TLR4 LRR9-13 or 18–20 with the human
residues did not affect signalling to RSLPS, nor did the horse
residues confer signalling onto human TLR4 (data not shown).
This suggests species-specific amino acids in LRR9-13 and 18–
20 contribute to RSLPS signalling only in the presence of
horse LRR14-17. None of these chimeras signalled to RSLPS
when transfected with human MD-2 (not shown).
Horse models of TLR4-MD-2 possess unique structural
features resulting in distinctive lipid-binding cavities
compared to human and mouse structures
The sequences of horse TLR4 and MD-2 proteins are more
closely related to human than to mouse, even though the
functionality of the complex stands out compared to both. As
the crystal structures are known for both human and mouse
active complexes we decided to generate models for the horse
complex based on both of them independently (and thus
generating a human-based model and a mouse-based one) and,
together in an averaged model [4,11]. The root mean square
deviations between the different models are within 2 A˚ (0.6 A˚
for the averaged model and 1.8 A˚ for the mouse model
compared to the human one). For TLR4, the Ca trace deviates
in the convex region leading to a change in the overall
curvature of the receptor’s ectodomain. The alignment of the
central domain (where the dimerisation interface lies) results in
shifts of 3–7 A˚ at the N- and C-terminal ends respectively
between human and mouse models (the C-terminal end of the
ectodomain being the external juxtamembrane domain of the
receptor). In MD-2, loops between the second and the third b-
strand L2-3 (residues 37–44), the loop that bares the LPS-
binding motif between the seventh and the eight b-strand L7-8
(residues 122–129), and the following one L8-9 (residues 140–
143) adopt different conformations, whereas the Ca trace of
the secondary structural elements are overall well conserved.
These variations in structure lead to a cavity of 1250 A˚2/
2510 A˚3 for the mouse-based horse model against 1200 A˚2/
2305 A˚3 for the human-based horse model, and represent a
10% difference in volume. The human MD-2 cavity (1100 A˚2/
2370 A˚3) is largest of all, with the mouse cavity smallest
(1060 A˚2/2090 A˚3). Docking was performed on the averaged
model (1200 A˚2/2330 A˚3).
Figure 3. RSLPS requires specific residues within horse MD-2 and TLR4, yet is independent of CD14. HEK293 cells were transiently
transfected with combinations of human and horse TLR4 and MD-2, with or without horse CD14, and reporter constructs NF-kB-luc and phRG-TK.
Cells were stimulated 48 hours later for 6 hours with 100 ng/ml RSLPS, 10 ng/ml ECLPS, 100 ng/ml RSLPS+10 ng/ml ECLPS, or medium alone. Data
are from a representative experiment (n = 3 experiments) and expressed as triplicate mean6SEM for that experiment, relative to the maximum ECLPS
response. A) Cells were transfected with different combinations of human and horse TLR4 and MD-2. B) Horse TLR4/MD-2 was transfected with and
without CD14. C) MD-2 mutants were transfected with horse TLR4/CD14. D) TLR4 mutants were transfected with horse MD-2/CD14.
doi:10.1371/journal.pone.0098776.g003
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Docking studies to TLR4/MD-2 generates biologically
relevant ligand poses
We used molecular docking to propose how RSLPS interacts
with MD-2 and differs between human and horse TLR4-MD-2
complexes. An initial RSLPS-bound model was generated in
which the acyl chains extend away from the phosphorylated
diglucosamine core. Docking generated poses that accommodate
the longest chain (R20) by folding it back on itself to fit into the
hydrophobic pocket in MD-2, which is also seen for the C18 chain
of eritoran [10]. As for ligands previously studied at a structural
level, the head group is exposed to the solvent and interacts with
charged residues at the opening of the MD-2 cavity.
RSLPS could adopt two orientations regarding positioning of
the phosphorylated diglucosamine core, with the 1-PO4 group
pointing toward either the primary TLR4 binding site or the
dimeric interface. The latter is observed for the horse TLR4-MD-
2 active complex, whereas the former is observed for human
complexes with either MD-2 alone or both TLR4/MD-2.
Interestingly, areas of contact made by the lipid moiety of RSLPS
also shift within the MD-2 pocket. In human complexes, the lipid
tails lean more towards the b-sheet formed by strands 5 and 6. In
the horse complex, the acyl chains are found in the vicinity of the
opposite b-sheet formed by strands 4–7 and the LPS binding motif
mentioned earlier, L7-8, that contains the critical residue F126.
Comparisons of human- and horse-bound RSLPS exemplify how
subtle changes in ligand binding lead to crucial differences in
biological activity.
Docking highlights species-specific differences in lipid A
positioning
Structural models of RSLA bound to inactive MD-2 and active
TLR4/MD-2 dimer complex were generated for human and
horse complexes and aligned to available crystal structures of
ECLPS and lipid IVa complexes with human and mouse proteins
(figure 4A). One hundred 3D arrangements were generated per
calculation. Only the biologically relevant ones were analysed (ie.
lipid tails within the hydrophobic cavity of MD-2). Overall, TLR4
and MD-2 proteins models and crystal structures from different
species superimpose well (with a root mean square deviation ,2 A˚
over about 9,600 atoms). Comparison of modelled RSLA to
experimentally characterised complexes showed that all ligands
have slightly different conformations (figure 4B). RSLA and lipid A
acyl chains follow a broadly similar shape, and fill a greater
volume of the MD-2 pocket than lipid IVa. It is clear, however,
that the acyl chains of both RSLA and lipid IVa fail to follow the
acyl chains of lipid A exactly. These differences cannot be
explained by the different species of MD-2, since the overlap of
lipid A-bound human and mouse MD-2 is greater than that of the
two horse MD-2 3D models. Concomitantly with the position of
the F126 loop, significant differences are observed in the
positioning of the phosphate groups of the ligands. In particular,
the 49-PO4 groups are variably positioned facing either the
primary TLR4 side or towards the dimeric TLR4* direction. In
the horse active complex, the R2 chain of RSLA, like lipid A,
protrudes from the MD-2 pocket to contact TLR4*, whereas R2
of lipid IVa is folded back into the pocket and fails to contact the
dimerisation interface (figure 4A and 4B). The tip of RSLA R2
points towards P442* of horse TLR4* at a distance suitable for van
der Waals contacts (,4.5 A˚). The other acyl chains of RSLA
penetrate more deeply into the MD-2 pocket, with a concomitant
lowering of the diglucosamine backbone and rotation of the 1-PO4
away from the primary TLR4 site.
R385 and P442 of horse TLR4 are required for the agonist
activity of RSLA
Molecular modelling identified that R385 and P442 were likely
to be important residues for the agonist activity of RSLPS, and of
these R385 of horse TLR4 is essential for lipid IVa agonist activity
[9]. We therefore transfected HEK293 cells with human TLR4
G384R (hG384R) or horse TLR4 R385G (eqR385G), together
with horse MD-2, and stimulated the cells with RSLPS. A modest
reduction in the agonist activity of RSLPS was observed with
eqR385G, but the mutation did not abrogate the signal as was
seen previously for lipid IVa (figure 5A) [9]. Human TLR4
G384R did not signal to RSLPS with horse MD-2 and remained
an antagonist of ECLPS. Neither construct signalled to RSLPS
with human MD-2 (not shown). R385 is therefore involved in
RSLPS agonist activity, but other residues are also required.
Mutation of P442 to the corresponding human residue (P442S)
also conferred a modest reduction in RSLPS signal. It did not,
however, affect the signal to lipid IVa (figure 5B), confirming that
the predicted difference in positioning of the ligand R2 chains and
their interactions with the TLR4* interface are important. R385G
and P442S single mutations of horse TLR4 each caused a modest
reduction in RSLPS signal, yet neither alone caused abrogation. A
horse TLR4 mutant was therefore constructed containing both of
these mutations. Combined mutation of R385G and P442S
caused a complete loss of the RSLPS signal, confirming the
importance of these two residues in RSLPS agonist activity at
horse TLR4 (figure 5A). The complementary double mutation
G384R-S441P within human TLR4 was unable to confer
signalling to RSLPS, however, indicating other residues are also
involved in recognition of RSLPS as an agonist.
Discussion
A key question generated by solving the LPS-bound TLR4/
MD-2 structures was whether there would be similar molecular
determinants when other lipid A variants bound to the receptor
complex [4]. Comparative biology studies have played an
important part in understanding how different lipid A structures
drive the formation of active TLR4/MD-2 complexes. Human
and horse TLR4 and MD-2 are more closely related to one
another than either are to the mouse receptors, yet RSLPS is an
agonist at horse TLR4/MD-2 and an antagonist at both the
mouse and human receptors. In this study, we have confirmed the
importance of R385, but we have also identified P442 as a key
player in conferring RSLPS agonist activity at TLR4.
Acyl chain number has long been recognised as an important
structural determinant of whether a given lipid A behaves as an
agonist or antagonist [6,7,8,9]. Lipid IVa and RSLPS are both
partial agonists at horse TLR4 but have different efficacies.
Relative to ECLPS (100%), lipid IVa and RSLPS have 55% and
88% efficacies respectively (figure 2A) [15]. The decreased efficacy
of these lipids in comparison to ECLPS is probably caused in part
by the reduced acyl chain number, which alters their positioning
within the MD-2 pocket and thus the effective formation of the
active TLR4/MD-2 heterotetramer. The MD-2-occupying chains
of RSLA and lipid IVa probably share some, but not all, of the
residue contacts formed between lipid A and MD-2, leading to a
reduced signal. This subtle difference in acyl chain position is likely
to underlie the different dependence of lipid IVa and RSLPS on
residues 80–107 of horse MD-2, and makes identification of
suitable point mutation candidates difficult. Instead, a more
holistic effect of this region on signalling is likely to derive from a
species difference in overall charge and/or flexibility, since the
major non-conserved residues in horse/human comprise E86/
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N86 and M89/K89 respectively. The effect of subtle positional
differences within MD-2 is also observed in signalling by lipid IVa
at mouse TLR4/MD-2, for which a very small reduction in
efficacy can be explained by subtle differences in ligand-receptor
interaction [5].
In addition to the extensive lipid A acyl chain interactions
formed with MD-2 and TLR4*, the two diglucosamine
backbone phosphate groups are supportive of ligand position-
ing and thought to be important for agonist activity [4]. K341,
K362 and K388* of human TLR4 are involved with
positioning of the 1-PO4 of lipid A, whereas G384 is not
because of its lack of a side chain. In the overlapped human/
lipid A and horse/RSLA structures, R385 of horse TLR4 is
situated 9.4 A˚ away from the 1-PO4 of lipid A in the human-
bound position (not shown). R342, K363 and K389*, however,
sit much closer to this moiety, and so probably contribute to
lipid A positioning by 1-PO4 interaction (not shown). These
residues are also located close to the 1-PO4 of RSLA, and so,
together with R385, probably position RSLA similarly to lipid
A. Apart from R385, lipid IVa 1-PO4 appears only to make
contact with K389* (at 6.1 A˚). R385 is therefore essential for
lipid IVa signalling, as it provides alternative 1-PO4 long-range
electrostatic attraction. The increased distance between RSLA
1-PO4 and R385 (8.5 A˚) relative to lipid IVa 1-PO4 probably
explains the difference in effect observed by R385G mutation
between these two ligands (not shown).
In the human TLR4/MD-2/lipid A crystal structure, R264
and K362 of TLR4 and S118 of MD-2 all interact with lipid A
49-PO4 via charge/polar interactions [4]. These charges are
conserved in horse TLR4 (K264, K363 and S118) and so are
also probably involved in lipid A 49-PO4 positioning. Com-
parison with lipid IVa and RSLA demonstrates different 49-
PO4 positions for the ligands. Lipid A 49-PO4 sits centrally
between K264, K363 and S118, lipid IVa 49-PO4 is skewed
towards K264, and RSLA 49-PO4 is pushed towards S118 of
MD-2 (not shown).
One of the key structural differences between RSLA and
lipid IVa is the presence of the R20 chain. In the docking
model for RSLA, this unsaturated and extended chain is
predicted to be greatly bent within the horse MD-2 hydro-
phobic pocket (figure 4A). In the human TLR4/MD-2/lipid A
crystal structure, the R20 chain of lipid A remains straight and
contacts human MD-2 deep within the pocket. Since an R30
chain is also present in lipid A, the MD-2 pocket is occupied
fully. This forces the R2 chain out of the pocket to contact
TLR4*. R30 is absent in RSLA, therefore folding of the
extended R20 may produce a similar effect on MD-2
occupation and encourage R2 protrusion. In the mouse lipid
IVa crystal, the R2 chain is positioned slightly away from
TLR4*, but this is not as pronounced as for the horse model.
Lipid IVa also sits much higher within mouse MD-2 than it is
predicted to in the horse model. This difference in positioning
may negate the need for full R2 protrusion, and explain why
lipid IVa is able to activate mouse TLR4/MD-2 more
efficiently than it can horse. RSLA is predicted to sit much
lower within MD-2 than either lipid IVa conformation, yet R2
protrusion seems to compensate for this, and allows the ligand
to activate the complex strongly. R2-TLR4* interaction is
therefore probably important for a strong signal at TLR4 if
other interactions are sub-optimal. Lipid IVa in the horse-
bound conformation fails to form either optimal 1-PO4/49-
PO4 interactions or strong R2-TLR4* interaction, which
probably causes the observed lower efficacy of this ligand in
the horse relative to that in the mouse [15]. Lipid A, on the
other hand, satisfies both sets of interactions, explaining its
high efficacy relative to the other ligands. Our study highlights
the subtle interplay between van der Waals contacts and ionic
interactions involved in the activation process, with compen-
satory effects depending on the ligand’s geometry.
The difference in CD14 requirement by ECLPS and RSLPS
for signalling is curious. Although CD14 presents lipid A
monomers to the TLR4/MD-2 complex, the complete
biological role of CD14 in LPS signalling is still not fully
Figure 4. RSLA and lipid IVa sit differently within the MD-2 pocket. A) Docking models of RSLA and lipid IVa bound to horse TLR4/MD-2 were
overlaid to assess ligand and receptor positioning. The acyl chains of RSLA (blue) sit more deeply in the MD-2 (pink) pocket than lipid IVa (green), and
the R2 chain of RSLA protrudes from the MD-2 pocket to contact TLR4* (grey). The 1-PO4 is also moved away from TLR4 due to lowering of the
diglucosamine backbone. B) Overlay of RSLA (blue; horse model), lipid IVa (green; horse model) and lipid A (red; human crystal) in situ in the MD-2
pocket. TLR4 and MD-2 have been removed for clarity. The PO4 groups and acyl chains of all three ligands sit somewhat differently to one another
within the pocket. Lipid A and RSLA appear to occupy a similar volume within the pocket.
doi:10.1371/journal.pone.0098776.g004
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understood [23]. The relative independence of RSLPS from
CD14 may reflect a simple tendency of the ligand to form
smaller aggregates. Alternatively, differences in O-antigen
between ECLPS and RSLPS may underlie a differing need
for facilitation by CD14. The presence of O-antigen does not
change the activity of RSLPS or RSLA in the presence or
absence of CD14 (data not shown). This is in contrast to other
bacterial LPS species such as Salmonella, for which CD14 is
required in both MyD88 and TRIF-dependent signalling to
smooth LPS, but only TRIF-dependent signalling to rough
LPS and lipid A [24]. Further investigation using LPS from a
wide variety of bacterial species is required to explore this
fully.
In summary, the results of this study demonstrate differences in
predicted binding and efficacy between lipid A, RSLA and lipid
IVa. In modelling studies, RSLA shares more similarities in
binding the active TLR4/MD-2 complex with lipid A than it does
lipid IVa, which presumably precipitates different efficacies for
RSLPS, ECLPS and lipid IVa. We show that very subtle
differences in ligand positioning can precipitate significant
pharmacological effects, and that this is likely the result of a
subtle interplay between ionic interactions and van der Waals
forces. We also conclude that the fluid nature of the lipid tail of
LPS leads to an overall effect tangibly different to the well-defined
electrostatic anchoring [25]. This study highlights the importance
of regions outside the ligand and dimerisation binding area for the
signalling output of TLR4, which indicates a cooperative binding
mechanism. This mechanism is particularly relevant in the context
of single nucleotide polymorphism analysis, and will also
ultimately impact development of therapeutic TLR4 ligands.
The heterogeneity of naturally-derived RSLPS is particularly
relevant to the development of synthetic therapeutic ligands, and
this heterogeneity may even be the key to unlocking the potential
for the use of these ligands as drugs.
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